Business Description
![Vertex Pharmaceuticals Inc Vertex Pharmaceuticals Inc logo](https://static.gurufocus.com/logos/0C000009I3.png?14)
Vertex Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US92532F1003
Share Class Description:
VRTX: Ordinary SharesCompare
Compare
Traded in other countries / regions
VRTX.USA0QZU.UKVRTX.MexicoVRTX34.BrazilVX1.GermanyVRTX.Austria1VRTX.Italy IPO Date
1991-07-31Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 14.1 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | 0.14 | |||||
Interest Coverage | 102.08 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 15.73 | |||||
Beneish M-Score | -2.06 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 17.2 | |||||
3-Year EBITDA Growth Rate | 12.3 | |||||
3-Year EPS without NRI Growth Rate | 13.8 | |||||
3-Year FCF Growth Rate | 3.5 | |||||
3-Year Book Growth Rate | 26.8 | |||||
Future 3-5Y EPS without NRI Growth Rate | 12.53 | |||||
Future 3-5Y Total Revenue Growth Rate | 8.83 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 35.16 | |||||
9-Day RSI | 46.94 | |||||
14-Day RSI | 54.02 | |||||
6-1 Month Momentum % | 9.19 | |||||
12-1 Month Momentum % | 27.4 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.5 | |||||
Quick Ratio | 3.29 | |||||
Cash Ratio | 2.68 | |||||
Days Inventory | 184.38 | |||||
Days Sales Outstanding | 57.33 | |||||
Days Payable | 97.04 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.3 | |||||
Shareholder Yield % | 0.66 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 86.86 | |||||
Operating Margin % | 43.2 | |||||
Net Margin % | 39.46 | |||||
FCF Margin % | 34.16 | |||||
ROE % | 24.35 | |||||
ROA % | 18.66 | |||||
ROIC % | 45.25 | |||||
ROC (Joel Greenblatt) % | 330.95 | |||||
ROCE % | 26.61 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 30.41 | |||||
Forward PE Ratio | 28.9 | |||||
PE Ratio without NRI | 27.68 | |||||
Shiller PE Ratio | 71.9 | |||||
Price-to-Owner-Earnings | 38.82 | |||||
PEG Ratio | 0.67 | |||||
PS Ratio | 12 | |||||
PB Ratio | 6.53 | |||||
Price-to-Tangible-Book | 7.28 | |||||
Price-to-Free-Cash-Flow | 35.12 | |||||
Price-to-Operating-Cash-Flow | 30.98 | |||||
EV-to-EBIT | 23.18 | |||||
EV-to-Forward-EBIT | 22.15 | |||||
EV-to-EBITDA | 22.27 | |||||
EV-to-Forward-EBITDA | 21.34 | |||||
EV-to-Revenue | 10.95 | |||||
EV-to-Forward-Revenue | 10.37 | |||||
EV-to-FCF | 32.04 | |||||
Price-to-Projected-FCF | 2.28 | |||||
Price-to-Median-PS-Value | 0.82 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.11 | |||||
Price-to-Graham-Number | 2.99 | |||||
Price-to-Net-Current-Asset-Value | 15.29 | |||||
Price-to-Net-Cash | 25.21 | |||||
Earnings Yield (Greenblatt) % | 4.31 | |||||
FCF Yield % | 2.88 | |||||
Forward Rate of Return (Yacktman) % | 22.36 |